Claudius Mahr, DO
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1770659526
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (37.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Abiomed at 53.0% of the total. Reporting peaked in 2024 at $23,548 and has fallen 77.6% since, to $5,277 in 2025.
Across 232 payments — averaging $373.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$46K
- Medtronic$32K
- Abbott$6K
- Paragonix Technologies, Inc.$514
- Atricure, Inc.$291
- Alnylam Pharmaceuticals Inc.$227
- plus $2K from 22 others
Across 65 payments — averaging $3806.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$90K
- Endotronix, Inc.$73K
- Novartis$66K
- Abbott$19K
What the payments were for
- Consulting fees$22,66426%
- Speaking & faculty fees$17,63720%
- Travel & lodging$32,76638%
- Food & beverage$13,52316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 77 | $45,915 |
| Medtronic(2 entities) | 36 | $32,263 |
| Abbott | 53 | $5,838 |
| Paragonix Technologies, Inc. | 6 | $514 |
| Atricure, Inc. | 5 | $291 |
| Alnylam Pharmaceuticals Inc. | 5 | $227 |
| E.r. Squibb & Sons, L.L.C. | 8 | $184 |
| Edwards Lifesciences | 1 | $166 |
| Cvrx, Inc. | 1 | $157 |
| Kestra Medical Technology Services, Inc. | 6 | $155 |
| Novartis | 7 | $127 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $121 |
| Endotronix, Inc. | 1 | $109 |
| Boston Scientific | 2 | $61 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Johnson & Johnson | 3 | $47 |
| Analog Devices Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Merck | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Novo Nordisk | 1 | $26 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Pfizer | 1 | $26 |
| Bayer | 1 | $22 |
| Shockwave Medical, Inc | 1 | $22 |
| Invivyd Inc | 1 | $15 |
| Kamada Ltd. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$41,879
- HeartWare HVAD$23,842
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,223
- HeartMate 3 Left Ventricular Assist Device$869
- Paragonix SherpaPak Cardiac Transport System$837
- HeartMate 3 Left Ventricular Dev$682
- HeartMate Touch$622
- LUNGguard$343
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$168
- INSPIRIS RESILIA aortic valve$166
- ATRICLIP LAA EXCLUSION SYSTEM$162
- EPI-EASE EPICARDIAL ACCESS SYSTEM$162
- SYNERGY ABLATION SYSTEM$162
- SherpaCool Box$161
- Barostim Neo System$157
- AMVUTTRA$127
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$109
How this compares
$86,590 in reported general payments places this provider in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$717K
- Martin BerkDallas$379K
- Shelley HallDallas$254K
- Maryjane FarrDallas$148K
- Kartik TelukuntlaDallas$80K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
- Nicholas HendrenDallas$12K
- Brian HsiDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.